Are there any contraindications for a patient with von Willebrand disease taking Aldactone (spironolactone) and Primolut-N (norethisterone) and Metformin for Polycystic Ovary Syndrome (PCOS) and hirsutism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

There are no absolute contraindications between von Willebrand disease and the medications Aldactone (spironolactone), Primolut Nor (norethisterone), and metformin for PCOS and hirsutism treatment, but careful monitoring is recommended. The patient with von Willebrand disease should be aware of the potential risks and benefits of these medications.

  • Spironolactone may increase bleeding risk slightly due to its anti-androgenic effects, though this is generally mild 1.
  • Norethisterone (Primolut Nor) can actually be beneficial in von Willebrand disease as it may reduce menstrual bleeding.
  • Metformin has no significant impact on bleeding risk and is safe to use. The patient should inform any healthcare providers about her von Willebrand disease before procedures, continue any prescribed treatments for the bleeding disorder, and report any unusual bleeding promptly. The benefits of treating PCOS and hirsutism typically outweigh the minimal risks in most patients with mild to moderate von Willebrand disease, but individualized assessment is important 1. It is essential to weigh the potential benefits of these medications against the potential risks and to closely monitor the patient's condition to minimize any adverse effects. In general, the use of these medications in patients with von Willebrand disease requires careful consideration and monitoring, but they can be a valuable treatment option for managing PCOS and hirsutism. Regular follow-ups with a healthcare provider are necessary to monitor bleeding patterns and adjust treatment as needed. By carefully evaluating the potential risks and benefits, healthcare providers can make informed decisions about the use of these medications in patients with von Willebrand disease.

From the FDA Drug Label

4 CONTRAINDICATIONS Spironolactone is contraindicated in the patients with: Hyperkalemia Addison’s disease Concomitant use of eplerenone

The patient has von Willebrand disease and will be taking Aldactone (spironolactone), Primolut Nor, and Metformin for PCOS and hirsutism.

  • There is no direct information in the provided drug label that mentions von Willebrand disease as a contraindication for spironolactone.
  • The contraindications listed are Hyperkalemia, Addison’s disease, and concomitant use of eplerenone. Based on the provided information, there is no direct contraindication mentioned for the patient's condition, but it is crucial to consider the patient's overall health and potential interactions with other medications 2.

From the Research

Medication Interactions and Contraindications

  • The patient has von Willebrand disease and is taking Aldactone, Primolut Nor, and Metformin for PCOS and hirsutism.
  • There is no direct evidence of contraindications between these medications and von Willebrand disease in the provided studies 3, 4, 5, 6, 7.
  • However, it is essential to consider the potential effects of these medications on the patient's bleeding disorder.
  • Hormonal treatments, such as Primolut Nor, are commonly used to manage heavy menstrual bleeding in women with von Willebrand disease 3, 5.
  • There is no mention of Aldactone or Metformin in the context of von Willebrand disease in the provided studies.
  • It is crucial to monitor the patient's condition and adjust the treatment plan as needed to minimize the risk of bleeding complications.

Treatment Considerations

  • The treatment of von Willebrand disease typically involves desmopressin, antifibrinolytics, and VWF concentrates 3, 5, 6.
  • The choice of treatment depends on the type and severity of the disease, as well as the patient's symptoms and medical history.
  • Women with von Willebrand disease may require additional treatment for heavy menstrual bleeding, such as hormonal therapies 5.
  • Interdisciplinary management of childbirth and prophylaxis in the postpartum period are necessary to reduce the risk of postpartum hemorrhage 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Von Willebrand Disease: Current Status of Diagnosis and Management.

Hematology/oncology clinics of North America, 2021

Research

von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis.

Haemophilia : the official journal of the World Federation of Hemophilia, 2021

Research

How I treat von Willebrand disease.

Thrombosis research, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.